Qyuns Therapeutics Co., Ltd. (HKG:2509)
Hong Kong · Delayed Price · Currency is HKD 15.08
-0.62 (-3.95%)
Jul 9, 2026, 4:08 PM HKT
Qyuns Therapeutics Revenue
In the year 2025, Qyuns Therapeutics had annual revenue of 806.96M CNY with 408.18% growth. Qyuns Therapeutics had revenue of 600.48M in the half year ending December 31, 2025.
Revenue
806.96M CNY
Revenue Growth
+408.18%
P/S Ratio
3.77
Revenue / Employee
2.39M CNY
Employees
337
Market Cap
3.39B HKD
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 806.96M | 648.17M | 408.18% |
| Dec 31, 2024 | 158.79M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 9.66M | -11.69M | -54.74% |
| Dec 31, 2021 | 21.35M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ocumension Therapeutics | 895.09M |
| Shandong Boan Biotechnology | 873.36M |
| BioDlink International Company | 831.99M |
| Medtide | 634.40M |
| Mirxes Holding Company | 166.32M |
| Guangzhou Innogen Pharmaceutical Group | 146.34M |
| Laekna | 118.76M |
| Antengene Corporation | 117.22M |